RHUMBLINE ADVISERS - PUMA BIOTECHNOLOGY INC ownership

PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 128 filers reported holding PUMA BIOTECHNOLOGY INC in Q3 2020. The put-call ratio across all filers is 1.91 and the average weighting 0.1%.

Quarter-by-quarter ownership
RHUMBLINE ADVISERS ownership history of PUMA BIOTECHNOLOGY INC
ValueSharesWeighting
Q3 2023$5,486
-25.5%
2,0860.0%0.00%
Q2 2023$7,363
-93.4%
2,086
-94.6%
0.00%
Q1 2022$112,000
-5.1%
38,775
+0.0%
0.00%
Q4 2021$118,000
-57.6%
38,771
-2.1%
0.00%
Q3 2021$278,000
-22.3%
39,609
+1.5%
0.00%
Q2 2021$358,000
-11.2%
39,041
-5.9%
0.00%
-100.0%
Q1 2021$403,000
-13.1%
41,489
-8.4%
0.00%0.0%
Q4 2020$464,000
+9.4%
45,269
+7.8%
0.00%0.0%
Q3 2020$424,000
-17.2%
42,009
-14.4%
0.00%0.0%
Q2 2020$512,000
+45.0%
49,071
+17.5%
0.00%0.0%
Q1 2020$353,000
-2.5%
41,771
+0.8%
0.00%0.0%
Q4 2019$362,000
-17.0%
41,422
+2.2%
0.00%0.0%
Q3 2019$436,000
-15.8%
40,529
-0.6%
0.00%0.0%
Q2 2019$518,000
-65.5%
40,771
+5.3%
0.00%
-66.7%
Q1 2019$1,501,000
+89.5%
38,705
-0.6%
0.00%
+50.0%
Q4 2018$792,000
-34.9%
38,938
+46.6%
0.00%0.0%
Q3 2018$1,217,000
-27.3%
26,553
-6.2%
0.00%
-33.3%
Q2 2018$1,674,000
-12.6%
28,294
+0.5%
0.00%
-25.0%
Q1 2018$1,916,000
-33.3%
28,161
-3.1%
0.00%
-33.3%
Q4 2017$2,872,000
-31.1%
29,055
-16.5%
0.01%
-33.3%
Q3 2017$4,167,000
+41.4%
34,794
+3.1%
0.01%
+28.6%
Q2 2017$2,948,000
+136.8%
33,733
+0.8%
0.01%
+133.3%
Q1 2017$1,245,000
+26.7%
33,462
+4.5%
0.00%
+50.0%
Q4 2016$983,000
-46.0%
32,033
+18.0%
0.00%
-60.0%
Q3 2016$1,821,000
+123.4%
27,152
-0.8%
0.01%
+150.0%
Q2 2016$815,000
+18.3%
27,358
+16.7%
0.00%0.0%
Q1 2016$689,000
-63.8%
23,451
-3.4%
0.00%
-66.7%
Q4 2015$1,904,000
+2.9%
24,283
-1.1%
0.01%0.0%
Q3 2015$1,851,000
-36.7%
24,557
-2.0%
0.01%
-33.3%
Q2 2015$2,925,000
-51.0%
25,054
-0.9%
0.01%
-47.1%
Q1 2015$5,971,000
+45.9%
25,289
+17.0%
0.02%
+41.7%
Q4 2014$4,093,000
-22.2%
21,623
-1.9%
0.01%
-25.0%
Q3 2014$5,260,000
+268.9%
22,048
+2.1%
0.02%
+300.0%
Q2 2014$1,426,000
-35.0%
21,604
+2.5%
0.00%
-42.9%
Q1 2014$2,194,000
-3.3%
21,067
-3.9%
0.01%0.0%
Q4 2013$2,270,000
+99.8%
21,924
+3.5%
0.01%
+75.0%
Q3 2013$1,136,000
+32.2%
21,174
+9.4%
0.00%
+33.3%
Q2 2013$859,00019,3500.00%
Other shareholders
PUMA BIOTECHNOLOGY INC shareholders Q3 2020
NameSharesValueWeighting ↓
Athyrium Capital Management, LP 1,792,114$5,108,0002.15%
Camber Capital Management LP 4,235,000$12,070,0000.52%
Kynam Capital Management, LP 579,915$1,653,0000.42%
GLOBEFLEX CAPITAL L P 419,322$1,195,0000.29%
Eversept Partners, LP 1,435,077$4,089,9690.29%
ARMISTICE CAPITAL, LLC 1,500,000$4,275,0000.08%
RICE HALL JAMES & ASSOCIATES, LLC 506,066$1,442,0000.07%
XTX Topco Ltd 36,130$103,0000.04%
State of Wyoming 20,732$59,0000.04%
Patriot Financial Group Insurance Agency, LLC 55,500$158,0000.03%
View complete list of PUMA BIOTECHNOLOGY INC shareholders